2[15]Onolo G, Melis MG, Formato M, Angius MF, Carboni A,Brizzi P, et al. Additive effects of simvastatin beyond its effects on LDL cholesterol in hypertensive type 2 diabetic patients[J].Eur J Clin Invest, 2000;30(11) :980 - 7
3[16]Velussi M, Cernigoi AM, Tortul C, Memi M. Atrovastatin for the management of type-2 diabetic patients with dyslipidemia. A mid-term (9-month) treatment experience [ J]. Diabetes Nutr Metab, 1999; 12(6) :407 - 12
4[17]Sposito AC, Mansur AP, Coelho OR, Nicolau JC, Ramires JA. Additional reduction in blood pressure after cholesterol-lowering treatment by statins (lovastatin or pravastatin) in hypercholesterolemic patients using angiotensin-converting enzyme inhibitors (enalapril or lisinopril)[J]. Am J Cardiol, 1999; 83(10): 1497 - 9
5[18]Borghi C, Prandin MG, Costa FV, Baccheli S, Degli Esposti D, Ambrosioni E. Use of statins and blood pres-ssure control in hypertensive patients with hypercholesterolemia [ J ]. J Cardiovasc Pharmacol, 2000;35(4) :549 - 55
6[19]D'Agostino RB, Kannel WB, Stepanians MND, Agostino LC.Efficacy and tolerability of lovastatin in hypercholesterolemia in patients with systemic hypertension[J]. Am J Cardiol, 1993;71(1):82-7
7[20]Jiang J, Roman RJ. Lovastatin prevents development of hypertension in spontaneously hypertensive rats [ J ]. Hypertension,1997;30(4):968-74
8[21]Wassmann S, Laufs U, Baumer AT, Muller K, Ahlbory K,Linz W, et al. HMG-CoA reductase inhibitors improve endothelial dysfunction in normocholesterolemic hypertension via reduced production of reactive oxygen species[ J]. Hypertension,2001; 137(6): 1450 - 7
9[22]Laufs U, La Fata V, Plutzky J, Liao JK. Upregulation of endothelial nitric oxide synthase by HMG-CoA reductase inhibitors[J]. Circulation, 1998;97(12): 1129 - 35
10[23]Kureishi Y, Luo Z, Shiojima I, Bialik A, Fulton D, Lefer DJ,Sessa WC, et al. The HMG-CoA reductase inhibitor simvastatin activates the protein kinase Akt and promotes angiogenesis in normocholesterolemic animals[J]. Nat Med, 2000; 6(9): 1004- 10
